Study guide

Chemotherapy Infusion Reaction and Extravasation Case Lab

OCN Oncology Certified Nurse Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: OCN Exam Orientation and Official Source Control

Official Sources and Credential Purpose Eligibility, Application, and Fees Exam Format, Scoring, Blueprint, and Generic Drugs PSI Scheduling, ATT, Test Day, and Results Blueprint-Based Study Plan and Readiness

2 Chapter 2: Care Continuum, Prevention, Survivorship, and End-of-Life Care

Health Promotion, Risk Reduction, and Epidemiology Screening, Early Detection, and High-Risk Referrals Navigation, Coordination, and Care Continuity Palliative Care, Advance Care Planning, and Goals Survivorship, Rehabilitation, Recurrence, and Late Effects Sexuality, Family Support, Discrimination, and Social Needs End-of-Life Care, Hospice, Bereavement, and Comfort Measures

3 Chapter 3: Oncology Science and Site-Specific Cancer Assessment

Carcinogenesis, Immunology, and Cancer Biology Genomic, Genetic Testing, and Biomarker Literacy Clinical Trials, Research Protocols, and Informed Participation Diagnostic Workup, Biopsy, Imaging, and Pathology Basics Staging, Grading, Prognosis, and Performance Status Common Cancer Patterns and Metastatic Sites Oncology Assessment, Data Clustering, and Escalation

4 Chapter 4: Professional Oncology Nursing Practice, Safety, and Standards

Scope, Standards, Nursing Process, and Documentation Collaboration, Communication, and Interprofessional Practice Safe Handling, PPE, Occupational Health, and Exposure Response Culturally Congruent Care, Advocacy, and Ethics Self-Care, Compassion Fatigue, Burnout, and Professional Development

5 Chapter 5: Treatment Modalities I - Surgery, Radiation, Transplant, Localized and Oral Therapy

Surgery and Procedural Oncology Nursing Care Radiation Therapy Principles, Toxicities, and Teaching Blood and Marrow Transplant Foundations Localized Therapy: Intrathecal, Intravesical, and Regional Care Oral Oncology Therapy Adherence, Safety, and Education Treatment Sequencing, Response Monitoring, and Care Coordination Modality-Specific Patient Teaching and Documentation

6 Chapter 6: Treatment Modalities II - Systemic Therapy, Immunotherapy, and Targeted Agents

Chemotherapy Foundations and Infusion Safety Biotherapy, Immunotherapy, and Immune-Related Adverse Events Targeted Therapy, Immune Cell, and Bispecific Antibody Basics Hormonal Therapy and Endocrine Cancer Treatment Considerations Vascular Access, Infusion Monitoring, and Extravasation Prevention Systemic Therapy Patient Education and Home Safety Therapy Response, Adherence, and Toxicity Escalation

7 Chapter 7: Symptom Management and Supportive Care

Symptom Assessment, Toxicity Grading, and Prioritization Hematologic, Immunologic, and Infection Supportive Care GI, GU, Nutrition, and Hydration Supportive Care Integumentary, Ostomy, Lymphedema, and Wound Care Respiratory, Cardiovascular, Neurologic, and Musculoskeletal Symptoms Pain Management, Pharmacologic, and Integrative Care Vascular Access Device Care and Supportive Care Coordination

8 Chapter 8: Oncologic Emergencies and Rapid Escalation

Sepsis, SIRS, Neutropenic Infection, and Shock Tumor Lysis, Hypercalcemia, SIADH, and Metabolic Emergencies Hypersensitivity, Anaphylaxis, and Infusion Reactions Spinal Cord Compression, SVC Syndrome, Increased ICP, and Obstructions DIC, VTE, Bleeding, and Thrombotic Emergencies Pneumonitis, Extravasation, and Local Therapy Emergencies Immune-Related Emergencies, CRS, ICANS, and Urgent Triage

9 Chapter 9: Psychosocial Dimensions of Oncology Care

Distress Screening, Emotional Response, and Crisis Care Cultural, Spiritual, Religious, and Language-Responsive Care Family, Caregiver Support, and Shared Decision-Making Sexuality, Fertility, Gender, and Body Image Concerns Learning Barriers, Health Literacy, and Patient Education Financial Toxicity, Support Systems, and Resource Referrals

10 Chapter 10: Mixed OCN Case Labs

New Diagnosis Navigation and Treatment Planning Case Lab Chemotherapy Infusion Reaction and Extravasation Case Lab Immunotherapy Toxicities and CRS ICANS Case Lab Radiation Surgery and Localized Therapy Case Lab Symptom Management Neutropenia Pain and Nutrition Case Lab Oncologic Emergency TLS SVC Cord Compression Case Lab Survivorship Palliative Psychosocial and Discharge Case Lab

11 Chapter 11: Final Review, High-Yield Tables, and OCN Exam-Day Readiness

Blueprint Quick Reference and Domain Triage High-Yield Oncology Safety and Emergency Tables Generic Drug Stems, Labs, and Supportive Care Patterns Final Week Practice Plan, Error Log, and Stamina Final 48 Hours, PSI Test Day, and Retake Planning

Chemotherapy Infusion Reaction and Extravasation Case Lab

Key Takeaways Explain This Topic AI

STOP the infusion first for any suspected hypersensitivity reaction or extravasation, then assess ABCs and notify the provider.

Paclitaxel and platinum agents are classic culprits; taxane reactions cluster in the first 10 minutes of cycles 1-2, platinum reactions appear after multiple cycles.

For vesicant extravasation, do NOT flush; leave the catheter, aspirate per policy, and apply cold (most vesicants) or warm (vinca alkaloids) compresses by drug class.

Dexrazoxane (Totect) is the antidote for anthracycline extravasation; hyaluronidase is used for vinca alkaloids; antidote choice is drug-specific.

Follow USP <800> hazardous-drug handling: PPE, closed-system transfer devices, spill kits, and 48-hour body-fluid precautions for patients at home.

Last updated: June 2026

  • Case Lab: Chemotherapy Infusion Reaction and Extravasation
  • Case Snapshot

A 61-year-old is receiving cycle 1 of paclitaxel after standard premedication (dexamethasone, an H1 blocker such as diphenhydramine, and an H2 blocker such as famotidine). Ten minutes into the infusion the patient reports chest tightness, flushing, dyspnea, and back pain. At a neighboring chair, a peripheral IV that earlier delivered a vesicant push now shows redness, swelling, and no blood return. Two time-critical problems: a hypersensitivity reaction and a possible extravasation .

First Priorities for an Infusion Reaction

For a suspected reaction, stop the infusion immediately . Keep IV access open with normal saline per policy and assess airway, breathing, circulation, vital signs, SpO2, skin, pain, mental status, and symptom onset. Call for help and notify the provider. Give emergency medications only per standing protocol or order: oxygen, antihistamine, corticosteroid, bronchodilator, IV fluids, and epinephrine for anaphylaxis. Do not restart the drug unless the provider directs a rechallenge and the patient is stable.

Paclitaxel reactions are frequently nonimmune (related to the Cremophor EL vehicle) and occur within the first few minutes of cycles 1-2; platinum reactions are usually true IgE-mediated hypersensitivity emerging after several cycles. Both are managed the same in the moment: stop, assess, treat, escalate.

Finding Likely Concern Immediate RN Response

Dyspnea, wheeze, hypotension, throat tightness Anaphylaxis / severe hypersensitivity Stop infusion, call for help, oxygen, epinephrine per protocol, notify provider

Flushing, mild rash, back pain, stable vitals Infusion reaction Stop infusion, assess, medicate per protocol, reassess before any restart

Burning, swelling, coolness, no blood return Extravasation or infiltration Stop infusion, leave catheter, aspirate per policy, notify provider

Anxiety alone with reassuring exam Distress vs. early reaction Assess fully; never dismiss symptoms without objective reassessment

Extravasation Recognition and Management

Extravasation is leakage of a vesicant or irritant into surrounding tissue; it can cause blistering, necrosis, and functional limb loss days to weeks later. Watch for burning, stinging, swelling, tightness, blanching, erythema, coolness, a damp dressing, a slowed infusion, or absent blood return. Central lines extravasate too, via catheter migration, rupture, or port-needle dislodgement.

When suspected, stop the infusion and do not flush the line, which would push more drug into tissue. Disconnect tubing, attempt aspiration of residual drug per policy, leave the catheter until aspiration is done, then notify the provider. Identify the agent, estimate the volume, mark and measure the area, and photograph per policy. Apply the correct compress by drug class: cold for most vesicants (anthracyclines, mitomycin) to localize the drug; warm for vinca alkaloids (vincristine, vinblastine) to disperse it. Antidotes are drug-specific: dexrazoxane (Totect) for anthracyclines, hyaluronidase for vinca alkaloids.

Always follow the institutional extravasation algorithm rather than memory.

Safe Handling and Patient Teaching

Hazardous-drug safety follows USP General Chapter <800> . Use appropriate PPE (chemo-rated double gloves, impervious gown, eye protection) for preparation, administration, disposal, and spill response. Prime tubing safely, use closed-system transfer devices (CSTDs) when required, and place waste in yellow chemotherapy containers, not red sharps boxes. Staff who are pregnant, breastfeeding, or trying to conceive follow institutional exposure guidance, and a spill kit must be within reach.

Patient and caregiver teaching after hazardous-drug therapy:

Use gloves to handle body fluids (urine, stool, vomit, blood) for about 48 hours after most regimens, per agency policy

Flush the toilet twice with the lid down; wash soiled linens separately

Store oral chemotherapy in original containers away from children and pets; never crush or split unless directed

  • Call for fever >=38.0 C, uncontrolled vomiting, or a missed/double oral dose
  • Rechallenge, Escalation, and Documentation

After a reaction, reassess vital signs, SpO2, lung sounds, skin, and pain at frequent intervals. Rechallenge belongs to the provider and protocol; if restarted, the rate is slower with closer monitoring. Recurrent reaction, hypotension, airway symptoms, or chest pain means stop again and escalate. Document onset time, drug, dose, rate, symptom sequence, objective findings, vitals, IV-site assessment, actions, medications given, provider notification, response, and follow-up.

For extravasation add site measurements, photographs, estimated volume, catheter status, aspiration attempt, antidote, compress type, limb instructions, and reassessment plan.

Vesicants, Irritants, and Common Traps

The OCN exam expects you to classify agents. Vesicants can cause tissue necrosis on extravasation and split into two groups: DNA-binding (anthracyclines such as doxorubicin, plus mitomycin), which cause progressive, late-developing injury, and non-DNA-binding (vinca alkaloids such as vincristine, vinblastine), which are more readily neutralized. Irritants (carboplatin, etoposide) cause local burning and inflammation without true necrosis. Only vesicants carry the highest extravasation stakes, and central venous access is preferred for continuous vesicant infusions to lower peripheral extravasation risk.

Key hazardous-drug and reaction facts:

Premedication for paclitaxel exists precisely because of the high early-reaction rate; the presence of premeds does not mean a reaction cannot happen.

Anaphylaxis is treated with intramuscular or IV epinephrine per protocol, oxygen, fluids, and antihistamines/steroids; epinephrine is the first-line drug, antihistamines are adjuncts.

USP <800> requires chemotherapy waste in yellow containers; placing it in red sharps boxes is a frequent wrong answer.

Body-fluid precautions of about 48 hours protect caregivers from cytotoxic metabolites excreted in urine, stool, sweat, and vomit.

Classic distractors in infusion items: slowing the rate instead of stopping (wrong for a true reaction), flushing a suspected vesicant line (worsens injury), and applying the wrong compress temperature for the drug class. The defensible answer almost always stops the exposure first, then assesses, treats per protocol, escalates, and documents objective reassessment rather than relying on the patient's reassurance that symptoms will pass.